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1. INTRODUCTION {#mgg3550-sec-0005}
===============

Coronary heart disease (CHD) is one of the most common cardiovascular diseases, and one of the most common causes of death and disability globally (Sacks et al., [2017](#mgg3550-bib-0025){ref-type="ref"}). The pathophysiological mechanism of coronary heart disease is atherosclerosis, which is characterized by the deposition of excessive cholesterol in the arterial intima (Lusk et al., [2014](#mgg3550-bib-0019){ref-type="ref"}). The majority of CHD cases can be explained by the interaction of genetic and environmental factors (Peyser, [1997](#mgg3550-bib-0022){ref-type="ref"}). Because CHD is an age‐related disease, however, interindividual variation in risk of CHD might result from variation in the rate of biological aging (Coronary Artery Disease, [1938](#mgg3550-bib-0010){ref-type="ref"}).

Telomeres are protein‐bound DNA repeat structures that are located at the extreme ends of chromosomal DNA where they play an important role in maintaining genomic stability (Rhyu, [1995](#mgg3550-bib-0023){ref-type="ref"}). They are also a marker of biological aging (Blasco, [2005](#mgg3550-bib-0006){ref-type="ref"}). In previous studies, mean leukocyte telomere length (LTL) was found to be a predictor of CHD events in middle‐age (Spyridopoulos et al., [2009](#mgg3550-bib-0029){ref-type="ref"}). A case--control study confirmed the association between shorter LTL and an increased risk of coronary artery disease in European populations, which supports the hypothesis that differences in biological aging might contribute to the differences in disease risk and age of CHD onset (Li et al., [2017](#mgg3550-bib-0018){ref-type="ref"}). In recent years, more studies have revealed that several genes and gene variants are strongly associated with CHD, including *TN1P1*, *MPHOSPH6* and *ZNF208*(Song et al., [2017](#mgg3550-bib-0028){ref-type="ref"}), *SH2B3* and *SMARCA4*(Ji et al., [2017](#mgg3550-bib-0014){ref-type="ref"}), *TERT*(Han et al., [2017](#mgg3550-bib-0013){ref-type="ref"}), and *APOB*(Al‐Bustan, Ismael, Al‐Serri, & Al‐Rashdan, [2017](#mgg3550-bib-0001){ref-type="ref"}).

*RTEL1* (OMIM: 608833) is a DNA helicase that plays important roles in setting telomere length, maintaining telomeres, and repairing DNA in mice (Barber et al., [2008](#mgg3550-bib-0003){ref-type="ref"}). Recently, genome‐wide association studies (GWAS) have shown that *RTEL1* dysfunction appears to be closely related to certain cancers and age‐related diseases such as lung cancer (Yan et al., [2016](#mgg3550-bib-0032){ref-type="ref"}), glioma (Du et al., [2014](#mgg3550-bib-0012){ref-type="ref"}), astrocytoma (Jin et al., [2015](#mgg3550-bib-0015){ref-type="ref"}, [2013](#mgg3550-bib-0016){ref-type="ref"}), stroke (Cai et al.[, 2017a](#mgg3550-bib-0007){ref-type="ref"}), and colorectal cancer (Li et al., [2016](#mgg3550-bib-0017){ref-type="ref"}). However, few studies have investigated the association between genetic variants in *RTEL1* and the risk of CHD. We performed a case--control study to analyze the association between six single nucleotide polymorphisms (SNPs) in *RTEL1*and the risk of CHD in a Chinese Han population.

2. MATERIALS AND METHODS {#mgg3550-sec-0006}
========================

2.1. Ethics statement {#mgg3550-sec-0007}
---------------------

The study protocol was approved by the ethics committee of Haikou People\'s Hospital. Written informed consent was obtained from all participants after a full explanation of the study. All samples were coded to protect donor identity. The experimental protocol was implemented in accordance with the approved guidelines.

2.2. Study subjects {#mgg3550-sec-0008}
-------------------

This study included 596 CHD patients and 603 healthy controls. All subjects in our study were recruited from Haikou People\'s Hospital, Hainan, China. Patients were unrelated subjects ages 19--83 years old. The controls were recruited from routine healthy examinations in the same hospital. Patients were diagnosed with CHD using standard coronary angiography. Coronary angiography had to reveal 50% narrowing of the lumina of at least one of the major coronary arteries for a patient to be included in the study. Subjects with myocardial infarction, stable angina, and unstable angina were classified as CHD subjects. Non‐CHD controls have no congenital heart disease, familial hypercholesterolemia, end‐stage renal disease, or known vasculitides.

2.3. SNP genotyping {#mgg3550-sec-0009}
-------------------

Five SNPs in *RTEL1*with minor allele frequencies (MAF) of \>0.05 were identified in an association analysis of a Beijing Chinese population. The selected SNPs were reported to be associated with CHD and other cardiovascular disease risk. The SNP was found within an intronic region and was unlikely to possess any functional significance, according to the RegulomeDB. The GTEx result for this SNP shows that it is not known to be associated with gene expression in the most relevant tissue (vascular or peripheral nerve); however, the SNP and the associated variants in LD are known as eQTLs in artery tissue ([Supporting information Table [S2](#mgg3550-sup-0001){ref-type="supplementary-material"}](#mgg3550-sup-0001){ref-type="supplementary-material"}).

A GoldMag‐Mini Purification Kit (GoldMag Co. Ltd. Xian City, China) was used to extract genomic DNA from whole‐blood samples. DNA samples were stored at −80°C prior to analysis. DNA concentrations were measured using a NanoDrop 2000 (Thermo Scientific, Waltham, Massachusetts, USA). Agena MassARRAY Assay Design 4.0 software was used to design a multiplexed SNP MassEXTEND assay, and SNP genotyping was performed using the Agena MassARRAY RS1000 with manufacturer protocols. The PCR primers for each SNP are shown in [Supporting information Table [S1](#mgg3550-sup-0001){ref-type="supplementary-material"}](#mgg3550-sup-0001){ref-type="supplementary-material"}. Agena Typer 4.0 software was used to perform data management and analyses.

2.4. Statistical analysis {#mgg3550-sec-0010}
-------------------------

All statistical analyses were performed using SPSS 19.0 software for Windows (SPSS, Chicago, IL). Allele and genotype frequencies were determined using direct counts. Hardy--Weinberg equilibrium values for each SNP were determined using an exact test to compare the expected frequencies of genotypes in controls. Allele and genotype frequencies in CHD patients and controls were calculated using chi‐squared and Fisher\'s exact tests. Associations between SNPs and the risk of steroid‐induced CHD were tested in genetic models using PLINK software (Version 1.07). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using unconditional logistic regression analysis with adjustment for gender and age (Bland & Altman, [2000](#mgg3550-bib-0005){ref-type="ref"}). Finally, the Haploview software package (version 4.2) and SHEsis software platform (<http://www.nhgg.org/analysis/>) were used to estimate pairwise linkage disequilibrium (LD), haplotype construction, and genetic association at polymorphism loci (Barrett, Fry, Maller, & Daly, [2005](#mgg3550-bib-0004){ref-type="ref"}; Shi & He, [2005](#mgg3550-bib-0026){ref-type="ref"}). All *p* values were two‐sided, and *p* ≤ 0.05 was considered statistically significant.

3. RESULTS {#mgg3550-sec-0011}
==========

3.1. Characteristics of the participants {#mgg3550-sec-0012}
----------------------------------------

A total of 596 CHD cases (376 men and 220 women; mean age, 61.44 ± 11.16 years) and 603 controls (469 men and 134 women; mean age, 48.24 ± 13.05 years) were included in the study. The clinical characteristics of the cases and controls are shown in Table [1](#mgg3550-tbl-0001){ref-type="table"}. There were no significant differences in the age and gender distributions between the case and control groups (*p* \< 0.05).

###### 

Basic characteristics

  Parameters       Case            Control         *p* value
  ---------------- --------------- --------------- -----------
  No               596             603             \<0.001
  Males            376 (63.1%)     469 (77.8%)     
  Females          220 (36.9%)     134 (22.2%)     
  Mean age         61.44 ± 11.16   48.24 ± 13.05   \<0.001
  ALT (U/L)        31.17 ± 2.13                    
  AST (U/L)        36.62 ± 2.15                    
  GGT (U/L)        44.59 ± 3.82                    
  TP (g/L)         66.43 ± 0.31                    
  GLU (mmol/L)     6.35 ± 0.11                     
  TG (mmol/L)      1.80 ± 0.06                     
  TC (mmol/L)      4.09 ± 0.07                     
  HDL‐C (mmol/L)   1.14 ± 0.01                     
  LDL‐C (mmol/L)   1.93 ± 0.03                     
  APOA1 (g/L)      1.27 ± 0.01                     
  APOB (g/L)       1.01 ± 0.02                     
  Lp(a)(mg/L)      240.1 ± 12.11                   
  PLT (109/L)      169.47 ± 3.55                   
  PCT (%)          1.14 ± 0.15                     
  MPV (fl)         13.12 ± 0.32                    
  PDW (%)          14.22 ± 0.16                    

*p* \< 0.05 indicates statistical significance.

ALT: alanine aminotransferase; apoA: apolipoprotein A; APOB: apolipoprotein B; AST: aspartate aminotransferase; GGT: gamma‐glutamyl transpeptidase; GLU: glucose; HDL: high‐density lipoprotein; LDL: low‐density lipoprotein; LP(a): lipoprotein; MPV: Mean Platelet Volume; PCT: plateletcrit; PDW: platelet distribution width; PLT: platelet; TC: total cholesterol; TG: triglyceride; TP: total protein.
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3.2. Associations between RTEL1 SNPs and CHD risk {#mgg3550-sec-0013}
-------------------------------------------------

Five SNPs within the *RTEL1* locus were genotyped in CHD patients and healthy controls (Table [2](#mgg3550-tbl-0002){ref-type="table"}). Using chi‐square tests, we determined that rs6010620 and rs4809324 were associated with a decreased risk of CHD (rs6010620: OR = 0.78, 95% CI = 0.65--0.93, *p* = 0.005; rs4809324: OR = 0.08, 95% CI = 0.04--0.16, *p* = 2.74E ‐ 21).

###### 

Allele frequencies in cases and controls and odds ratio

  SNP         Chromosome   Position   Allele   MAF     HWE *p*   OR (95% CI)   *p* [a](#mgg3550-note-0006){ref-type="fn"}   *p* [b](#mgg3550-note-0007){ref-type="fn"}   
  ----------- ------------ ---------- -------- ------- --------- ------------- -------------------------------------------- -------------------------------------------- -----------------
  rs6089953   20           62291008   G/A      0.261   0.280     0.840         0.91（0.76--1.09）                           0.297                                        0.0594
  rs6010620   20           62309839   G/A      0.265   0.317     0.500         0.77（0.65--0.93）                           **0.005^\*^**                                **0.001^\*^**
  rs6010621   20           62310872   G/T      0.263   0.271     0.837         0.96（0.80--1.15）                           0.667                                        0.133
  rs4809324   20           62318220   C/T      0.098   0.107     0.526         0.08（0.04--0.16）                           **2.7E‐21^\*^**                              **5.4E‐22^\*^**
  rs2297441   20           62327582   A/G      0.317   0.325     0.517         0.96（0.81--1.14）                           0.677                                        0.133

95% CI: 95% confidence interval; HWE: Hardy--Weinberg equilibrium; OR: odds ratio.

Bold highlights the value of P and OR(95%CI) with statistical significance.

*^\*^p* ^a^ * *\< 0.05 indicates statistical significance.

*^\*^p* ^b^ \< 0.01 indicates statistical significance.

*p*values were calculated from a chi‐square test or Fisher\'s exact test.

*p* values were adjusted by Bonferroni correction.
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3.3. Associations between genotype frequencies and CHD risk {#mgg3550-sec-0014}
-----------------------------------------------------------

As is shown in Table [3](#mgg3550-tbl-0003){ref-type="table"}, logistic regression analyses revealed that the rs6010620 polymorphism in the *RTEL1* gene conferred a decreased risk of CHD in the codominant model (adjusted: OR = 0.52, 95% CI: 0.31--0.88, *p* = 0.007 for the "G/G" genotype) and the recessive model (adjusted: OR = 0.49, 95% CI: 0.30--0.80, *p = *0.004 for the "G/G" genotype).

###### 

Genotypic model analysis of the relationship between SNPs and coronary heart disease risk

  SNPs           Model         Genotype      control                 case                OR (95% CI)   *p* [a](#mgg3550-note-0011){ref-type="fn"}‐value   *p* [b](#mgg3550-note-0012){ref-type="fn"}‐value
  -------------- ------------- ------------- ----------------------- ------------------- ------------- -------------------------------------------------- --------------------------------------------------
  Rs6089953      Codominant    A/A           311 (51.6%)             317 (53.3%)         1             0.71                                               0.142
  A/G            246 (40.8%)   245 (41.2%)   1.02 (0.78--1.33)                                                                                            
  G/G            46 (7.6%)     33 (5.5%)     0.81 (0.47--1.39)                                                                                            
  Dominant       A/A           311 (51.6%)   317 (53.3%)             1                   0.91          0.182                                              
  A/G‐G/G        292 (48.4%)   278 (46.7%)   0.98 (0.76--1.28)                                                                                            
  Recessive      A/A‐A/G       557 (92.4%)   562 (94.5%)             1                   0.41          0.082                                              
  G/G            46 (7.6%)     33 (5.5%)     0.80 (0.47--1.36)                                                                                            
  Log‐additive   ‐‐‐           ‐‐‐           ‐‐‐                     0.96 (0.77--1.18)   0.67          0.134                                              
  Rs6010620      Codominant    A/A           270 (47.2%)             315 (52.9%)         1             **0.007\***                                        **0.0014^\*^**
  A/G            241 (42.1%)   246 (41.3%)   1.19 (0.90--1.59)                                                                                            
  G/G            61 (10.7%)    35 (5.9%)     **0.52 (0.31--0.88)**                                                                                        
  Dominant       A/A           270 (47.2%)   315 (52.9%)             1                   0.79          0.158                                              
  A/G‐G/G        302 (52.8%)   281 (47.1%)   1.04 (0.79--1.36)                                                                                            
  Recessive      A/A‐A/G       511 (89.3%)   561 (94.1%)             1                   **0.004\***   **0.0008^\*^**                                     
  G/G            61 (10.7%)    35 (5.9%)     **0.49 (0.30--0.80)**                                                                                        
  Log‐additive   ‐‐‐           ‐‐‐           ‐‐‐                     0.90 (0.73--1.10)   0.31          0.062                                              
  Rs6010621      Codominant    T/T           318 (52.9%)             317 (53.2%)         1             0.76                                               0.152
  G/T            240 (39.9%)   244 (40.9%)   1.10 (0.84--1.45)                                                                                            
  G/G            43 (7.2%)     35 (5.9%)     0.98 (0.57--1.69)                                                                                            
  Dominant       T/T           318 (52.9%)   317 (53.2%)             1                   0.54          0.108                                              
  G/T‐G/G        283 (47.1%)   279 (46.8%)   1.09 (0.84--1.41)                                                                                            
  Recessive      T/T‐G/T       558 (92.8%)   561 (94.1%)             1                   0.83          0.166                                              
  G/G            43 (7.2%)     35 (5.9%)     0.94 (0.56--1.60)                                                                                            
  Log‐additive   ‐‐‐           ‐‐‐           ‐‐‐                     1.05 (0.85--1.29)   0.68          0.136                                              
  Rs4809324      Codominant    T/T           479 (79.4%)             457 (81.2%)         1             0.92                                               0.184
  T/C            119 (19.7%)   102 (18.1%)   0.96 (0.69--1.35)                                                                                            
  C/C            5 (0.8%)      4 (0.7%)      1.26 (0.30--5.25)                                                                                            
  Dominant       T/T           479 (79.4%)   457 (81.2%)             1                   0.88          0.176                                              
  T/C‐C/C        124 (20.6%)   106 (18.8%)   0.98 (0.70--1.36)                                                                                            
  Recessive      T/T‐T/C       598 (99.2%)   559 (99.3%)             1                   0.74          0.148                                              
  C/C            5 (0.8%)      4 (0.7%)      1.27 (0.31--5.28)                                                                                            
  Log‐additive   ‐‐‐           ‐‐‐           ‐‐‐                     0.99 (0.72--1.35)   0.95          0.190                                              
  Rs2297441      Codominant    G/G           271 (44.9%)             276 (46.3%)         1             0.86                                               0.172
  A/G            272 (45.1%)   262 (44%)     0.96 (0.73--1.26)                                                                                            
  A/A            60 (9.9%)     58 (9.7%)     1.09 (0.69--1.72)                                                                                            
  Dominant       G/G           271 (44.9%)   276 (46.3%)             1                   0.88          0.176                                              
  A/G‐A/A        332 (55.1%)   320 (53.7%)   0.98 (0.76--1.27)                                                                                            
  Recessive      G/G‐A/G       543 (90%)     538 (90.3%)             1                   0.64          0.128                                              
  A/A            60 (9.9%)     58 (9.7%)     1.11 (0.71--1.73)                                                                                            
  Log‐additive   ‐‐‐           ‐‐‐           ‐‐‐                     1.01 (0.83--1.23)   0.93          0.186                                              

95% CI: 95% confidence interval; OR: odds ratio; SNP: single nucleotide polymorphism.

Bold highlights the value of P and OR(95%CI) with statistical significance.

*\*p *﹤ 0.05 indicates statistical significance.

*^\*^p* ^b^ * *﹤ 0.01 indicates statistical significance.

*p* values were calculated by unconditional logistic regression analysis with adjustments for age and gender.

*p* values were adjusted by Bonferroni correction.
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3.4. Associations between haplotype analyses and CHD risk {#mgg3550-sec-0015}
---------------------------------------------------------

Linkage disequilibrium and haplotype analyses of the SNPs in the case and control samples were further studied. Haplotype analysis revealed the block in the *RTEL1* genes. *RTEL1* genes rs6089953, rs6010620, and rs6010621 had very strong linkage disequilibria (Figure [1](#mgg3550-fig-0001){ref-type="fig"}); compared to the "ATT" wild‐type, the "GTT" haplotype was associated with a decreased risk of CHD (OR = 0.03, 95% CI = 0.01--0.12, *p* \< 0.0001) (Table [4](#mgg3550-tbl-0004){ref-type="table"}).

![Linkage disequilibrium (LD) plots containing five SNPs from *RTEL1*](MGG3-7-na-g001){#mgg3550-fig-0001}

###### 

*RTEL1* haplotype frequencies and the association with coronary heart disease risk

      rs6010620   rs6010621   rs4809324   Case     Control   Freq     Without adjustment   With adjustment                       
  --- ----------- ----------- ----------- -------- --------- -------- -------------------- ----------------- ------------------- -------------
  1   A           T           T           0.735    0.67      0.7016   1                    ‐‐‐               1                   ‐‐‐
  2   G           G           T           0.166    0.168     0.1672   0.89 (0.71--1.12)    0.32              1.03 (0.80--1.33)   0.82
  3   G           G           C           0.0.97   0.105     0.1013   0.82 (0.62--1.09)    0.17              0.94 (0.68--1.29)   0.69
  4   G           T           T           0.002    0.054     0.029    0.03 (0.01--0.11)    \<0.001^\*^       0.03 (0.01--0.12)   \<0.001^\*^

95% CI: 95% confidence interval; OR: odds ratio.

*p*values were calculated from unconditional logistic regression analysis.

*p* values were calculated by unconditional logistic regression analysis with adjustments for age and gender.

\**p* ≤ 0.05 indicates statistical significance.
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4. DISCUSSION {#mgg3550-sec-0016}
=============

The present case--control study of 596 CHD patients and 603 healthy controls was designed to investigate the associations between five SNPs in the *RTEL1* gene and the risk of CHD in a Chinese Han population. We found that rs6010620 and rs4809324 were associated with a decreased risk of CHD. In addition, the "G~rs6010620~T~rs6010621~T~rs4809324~" *RTEL1* haplotype was associated with a decreased risk of CHD. Our findings have shed new light on the *RTEL1*polymorphisms that may contribute to the protection of CHD. Additionally, eQTL analysis based on the GTEx database (<https://gtexportal.org/home/>) indicated that the rs6010620 polymorphisms may alter the expression level of *RTEL1*in coronary artery tissues (Figure [2](#mgg3550-fig-0002){ref-type="fig"}).

![*RTEL1* (rs6010620) expression in coronary artery tissues](MGG3-7-na-g002){#mgg3550-fig-0002}

Regulator of Telomere Elongation Helicase 1 (*RTEL1*), an essential DNA helicase, is located in 20q13.3 and includes 40 exons. *RTEL1* disassembles a variety of DNA secondary structures to facilitate DNA replication, repair, and recombination processes, thereby helping to maintain telomere integrity (Vannier, Sarek, & Boulton, [2014](#mgg3550-bib-0030){ref-type="ref"}). Several studies have shown that a substantial proportion of the marked interindividual variation in mean telomere length is genetically determined (Slagboom, Droog, & Boomsma, [1994](#mgg3550-bib-0027){ref-type="ref"}). In combination, this suggests that individuals who have inherited and shorter telomeres might be more prone to coronary heart disease. It is thus possible that the association of shorter telomeres with an increased risk of coronary heart disease may have a genetic basis (Codd et al., [2013](#mgg3550-bib-0009){ref-type="ref"}). Any genetic susceptibility could be exacerbated or retarded by postnatal effects on telomere length. If true, this observation could not only partially explain the genetic basis of coronary heart disease, but also its variable age of onset.

Furthermore, previous studies have revealed overexpression of the *RTEL1* genomic locus in several cancers such as breast, lung, esophagus, gastric, and colorectal cancer (Muleris, Almeida, Gerbault‐Seureau, Malfoy, & Dutrillaux, [1995](#mgg3550-bib-0020){ref-type="ref"}). Additionally, a mouse model study revealed that *RTEL1* could support cell growth by participating in Wnt/β‐catenin signaling, which suggests that *RTEL1* may be considered to be an oncogene (Wu, Sandhu, Nabi, & Hao, [2012](#mgg3550-bib-0031){ref-type="ref"}). However, in the past decade, *RTEL1* variants have been associated with the decreased risk of several brain cancers and age‐related disease including glioma, astrocytoma, glioblastomas, and congenital dyskeratosis. In our study, we investigated six SNPs in *RTEL1*: rs6089953, rs6010620, rs6010621, rs2297440, rs4809324, and rs2297441. Among these SNPs, Ding Y et al., (Ding et al., [2017](#mgg3550-bib-0011){ref-type="ref"}) reported the presence of rs4809324 was associated with increasing the COPD risk. The presence of rs2297441 was found to be associated with Crohn\'s disease in Canadian children (Amre et al., [2009](#mgg3550-bib-0002){ref-type="ref"}). The presence of rs6010620 was found to increase the risk of glioma (Zhao, Bian, Zhu, Zou, & Tang, [2014](#mgg3550-bib-0033){ref-type="ref"}). Cai et al.[(2017b](#mgg3550-bib-0008){ref-type="ref"}) reported the associations between single nucleotide polymorphisms in the *RTEL1* gene and stroke risk, and the result showed that the rs6010620, rs6010621, and rs6089953 were associated with an increased risk of stroke. However, Olivier, Charbonnel, Amiard, White, and Gallego ([2018](#mgg3550-bib-0021){ref-type="ref"}) showed *RAD51* and *RTEL1* gene could compensate telomere loss and protect cell stability when telomere was absent. And another study indicated that the presence of rs6010620 and rs2297440 resulted in a decreased risk of astrocytoma (Jin et al., [2013](#mgg3550-bib-0016){ref-type="ref"}). Rong et al. ([2017](#mgg3550-bib-0024){ref-type="ref"}) found rs6089953, rs6010621, and rs2297441 were also associated with a decreased risk of HAPE. In our study, we found that the presence of rs6010620 and rs4809324 was associated with a decreased risk of CHD. This is consistent with previous research results. As far as we know, we are the first to report the association between the *RETL1* polymorphisms rs6010620 and rs4809324, and CHD risk. More studies should investigate these SNPs using more clinical data with bigger samples. This result may provide a new data to facilitate earlier diagnosis and promote early prevention, and shed light on the new candidate genes and new ideas for the study of subsequent occurrence mechanism of CHD. However, some potential limitations in our current study should be considered when analyzing the results. Our study only conducted preliminary basic research. Moreover, further functional studies and larger population‐based prospective studies are required to fully understand the genetic factors underlying CHD.

5. CONCLUSION {#mgg3550-sec-0017}
=============

Our results indicate that the rs6010620 and the rs4809324 polymorphisms in *RTEL1* are associated with CHD in a Chinese Han population. These SNPs may serve as prognostic biomarkers for CHD in the Chinese Han population.
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